Table 3.

Efficacy outcome (efficacy ITT population)*.

	Recently diagnosed (≤3 years) (n = 231)	Chronic (>3 years) (n = 358)
Mean PANSS positive subscale score, (SD)
Baseline	15.6 (4.8)	15.4 (5.0)
Endpoint	12.1 (4.7)	13.1 (5.4)
Mean change from baseline to endpoint	−3.6 (4.9)	−2.3 (4.9)
95% CI of mean change; p value†	−4.2, −2.9; <0.0001	–2.8, −1.8; <0.0001
Change from baseline to endpoint p value between subgroup test‡	0.0010
Mean PANSS negative subscale score, (SD)
Baseline	20.4 (5.3)	20.1 (5.5)
Endpoint	16.0 (5.5)	17.2 (6.1)
Mean change from baseline to endpoint	−4.4 (5.1)	−2.9 (5.5)
95% CI of mean change; p value†	−5.1, −3.8; <0.0001	–3.4, −2.3; <0.0001
Change from baseline to endpoint p value between subgroup test‡	0.0003
Mean PANSS general psychopathology score, (SD)
Baseline	36.6 (8.4)	35.2 (7.7)
Endpoint	29.5 (8.6)	30.8 (9.6)
Change from baseline to endpoint	−7.1 (8.4)	−4.4 (8.2)
95% CI of mean change; p value†	−8.2, −6.0; <0.0001	−5.3, −3.6; <0.0001
Change from baseline to endpoint p value between subgroup test‡	0.0001

*Only patients with a valid baseline measurement and at least one valid follow-up assessment were included.

^†Within-group difference was tested using the Wilcoxon signed-rank test.

^‡Between-group difference was tested using the Wilcoxon two-sample test.

CI: confidence interval; ITT: intent-to-treat; PANSS: Positive and Negative Syndrome Scale; SD: standard deviation.